Abbott Laboratories (ABT)

40.40
0.36 0.88
NYSE : Health Care
Prev Close 40.76
Open 40.64
Day Low/High 40.24 / 40.73
52 Wk Low/High 36.00 / 45.79
Volume 7.16M
Avg Volume 9.02M
Exchange NYSE
Shares Outstanding 1.73B
Market Cap 70.60B
EPS 2.90
P/E Ratio 61.97
Div & Yield 1.06 (2.60%)

Latest News

Abbott Announces U.S. Launch And First Commercial Use Of The New EnSite™ Precision Cardiac Mapping System

Abbott Announces U.S. Launch And First Commercial Use Of The New EnSite™ Precision Cardiac Mapping System

ENHANCED SYSTEM ALLOWS BETTER THREE-DIMENSIONAL IMAGES OF ARRHYTHMIAS IN THE HEART

Abbott Announces CE Mark For Its

Abbott Announces CE Mark For Its "Alinity S" Blood And Plasma Screening System

INNOVATIVE SOLUTION DESIGNED FOR BLOOD AND PLASMA SCREENING MAINTAINS HIGHEST LEVELS OF ACCURACY WHILE SUBSTANTIALLY INCREASING PRODUCTIVITY

Abbott Announces CE Mark For Its Alinity Ci-series Diagnostic Systems

Abbott Announces CE Mark For Its Alinity Ci-series Diagnostic Systems

NEXT GENERATION OF HARMONIZED SYSTEMS, COMBINED WITH RECENTLY LAUNCHED ALINIQ PROFESSIONAL SERVICES, PROVIDE A UNIQUE SOLUTION TO HELP LABS AND HOSPITAL SYSTEMS ACHIEVE MEASURABLY BETTER HEALTHCARE PERFORMANCE

What Exactly Are Investors Missing Out On?

Statistically, Friday's rally was not the best one.

Check These Dividend Dates

Must-own dates for some notable names.

What Pharma and Health Care Investors Should Watch for at JPM

What Pharma and Health Care Investors Should Watch for at JPM

The largest investor conference for the health care industry kicks off on Monday in San Francisco.

Husband of Top Trump Adviser Conway Said to Be a Finalist for U.S. Solicitor General

Husband of Top Trump Adviser Conway Said to Be a Finalist for U.S. Solicitor General

The lawyer is the husband of Trump adviser Kellyanne Conway and works in corporate litigation.

Abbott Labs: Diagnosing Growth in 2017

Abbott Labs: Diagnosing Growth in 2017

ABT could be on course for 10% earnings growth this year, but will investors reward the company with a higher share price?

Don't Be So Quick to Be Bullish

The ETF put/call ratio chart indicates some limited upside.

Here's Your Last Chance to Sell Shake Shack, 4 More 'Toxic Stocks' in 2016

Here's Your Last Chance to Sell Shake Shack, 4 More 'Toxic Stocks' in 2016

The S&P 500 may be ending 2016 with double-digit gains, but almost a third of the index's individual stocks are actually down this year. Here's how to avoid the laggards.

Abbott Acquisition Of St. Jude Medical Set To Close On January 4, 2017

Abbott Acquisition Of St. Jude Medical Set To Close On January 4, 2017

- CREATES A PREMIER MEDICAL DEVICE BUSINESS WITH LEADING POSITIONS IN CARDIOVASCULAR AND NEUROMODULATION MARKETS

Dump These 5 'Toxic Stocks' Before the New Year

Dump These 5 'Toxic Stocks' Before the New Year

Start 2017 on the right foot by selling your holdings in these five stocks.

Dividend Stock Picks Could Look Even Better in Coming Weeks

Dividend Stock Picks Could Look Even Better in Coming Weeks

Technical analysis shows investors interested in Boeing, Abbott Labs, Johnson & Johnson and Cardinal Health may increase returns by holding off on purchases.

Abbott Laboratories Can Merge With St. Jude Medical: FTC

Abbott Laboratories Can Merge With St. Jude Medical: FTC

The Federal Trade Commission says Abbott Laboratories can proceed with its proposed $25 billion acquisition of St. Jude Medical.

FTC Allows Abbott to Spin Off Units, Buy St. Jude Medical

FTC Allows Abbott to Spin Off Units, Buy St. Jude Medical

Abbott can now proceed with its $25 billion buy of St. Jude Medical.

Top 5 Dividend Stocks to Buy Now for 2017

Top 5 Dividend Stocks to Buy Now for 2017

Here is a look at some stocks that are poised for excellent dividend returns in 2017.

Top 10 Dividend Stocks You Need to Buy Now to Prepare for 2017

Top 10 Dividend Stocks You Need to Buy Now to Prepare for 2017

Here's a look at the 10 best dividend stocks to invest in for potential outperformance in 2017.

Choppiness Usually Ends With Some Sort of Decline

Typically, the best way to get sentiment to turn is to take the indexes down.

Edwards' Life Goes On Without Big M&A

Edwards' Life Goes On Without Big M&A

As the dominant player in the transcatheter aortic valve replacement market, Edwards doesn't 'need' large deals.

Bearish Bets: A Gold Producer, a Drug Giant and Other Stocks That Look Good Short

HIMX, GG, ABT, ILMN and ENT all were recently downgraded by TheStreet's Quant Ratings.

Trump Claims Next Corporate Victims, AT&T-TWX Kick Off Hearing: In Case You Missed It Wednesday

Trump Claims Next Corporate Victims, AT&T-TWX Kick Off Hearing: In Case You Missed It Wednesday

AT&T and Time Warner kicked off a hearing to defend their $84.5 billion merger. AT&T is no stranger to legal battles and anti-trust battles.

Abbott Looks to Kill Alere Deal

Abbott Looks to Kill Alere Deal

The medical device giant files a suit against Alere in the Delaware Court of Chancery hoping to walk away from their $7.9 billion merger agreement.

Abbott Seeks To Terminate Alere Acquisition

Abbott Seeks To Terminate Alere Acquisition

ALERE HAS LOST SIGNIFICANT VALUE DUE TO NUMEROUS DAMAGING BUSINESS DEVELOPMENTS THAT OCCURRED FOLLOWING THE MERGER AGREEMENT